Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and metronomic capecitabine in refractory GI cancers
NCT04932187Phase 1Unknown
- Sponsor
- Ruijin Hospital
- Start
- Aug 2021
- Primary completion
- Jul 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of camrelizumab in hepatobiliary carcinoma, pancreatic carcinoma and gastrointestinal carcinoma, sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
hepatobiliary carcinomapancreatic carcinomagastrointestinal carcinoma
Beyond the preview
Go deeper on NCT04932187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04932187.